Candel Therapeutics, Inc. (CADL): Price and Financial Metrics
CADL Price/Volume Stats
Current price | $1.58 | 52-week high | $1.95 |
Prev. close | $1.54 | 52-week low | $0.66 |
Day low | $1.53 | Volume | 30,600 |
Day high | $1.61 | Avg. volume | 83,239 |
50-day MA | $1.51 | Dividend yield | N/A |
200-day MA | $1.21 | Market Cap | 45.69M |
CADL Stock Price Chart Interactive Chart >
Candel Therapeutics, Inc. (CADL) Company Bio
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.
Latest CADL News From Around the Web
Below are the latest news stories about CANDEL THERAPEUTICS INC that investors may wish to consider to help them evaluate CADL as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning! |
Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409The FDA gives Fast Track designation to Candel's (CADL) lead candidate, CAN-2409 plus prodrug (valacyclovir), for the treatment of patients with pancreatic cancer. |
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic CancerNEEDHAM, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational adenovirus asset CAN-2409 plus prodrug (valacyclovir) for the treatment of patients with pancreatic ductal adenocarcinoma (PD |
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409Decreases workforce by approximately 50% and reduces commercial manufacturing expenses to prioritize spend towards topline clinical data readouts for CAN-2409 in non-small cell lung cancer, pancreatic cancer, and prostate cancer in 2024Prioritizes development of CAN-3110 in recurrent high-grade glioma and initiation of investigational new drug (IND)-enabling studies in second indicationPlans to broaden discovery partnership opportunities based on the enLIGHTEN™ Discovery PlatformExtends cash run |
Candel Therapeutics Inc (CADL) Reports Q3 2023 Financial Results and Clinical ProgressAdvancements in Viral Immunotherapy Trials and Financial Health |
CADL Price Returns
1-mo | -11.73% |
3-mo | 7.48% |
6-mo | 71.74% |
1-year | 14.29% |
3-year | N/A |
5-year | N/A |
YTD | 7.48% |
2023 | -17.88% |
2022 | -77.11% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...